Purpose: Few studies have examined the relationship between duration of oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer and mortality in routine practice. We examined the association between treatment with 50% versus >85% of a maximal course of adjuvant therapy (eight cycles of CAPOX, twelve cycles of FOLFOX) and mortality in stage III colon cancer. Methods: Using linked databases, we identified Ontarians aged ≥18 years at diagnosis of stage III colon cancer between 2007 and 2019. In the primary comparison, we compared patients who received 50% or >85% of a maximal course of adjuvant therapy; in a secondary comparison, we evaluated a dose effect across patients who received FOLFOX in one-cycle increments from six to ten cycles against >85% (more than ten cycles) of a maximal course of FOLFOX. The main outcomes were overall and cancer-specific mortality. Follow-up began 270 days after adjuvant treatment initiation and terminated at the first of the outcome of interest, loss of eligibility for Ontario’s Health Insurance Program, or study end. Overlap propensity score weights accounted for baseline between-group differences. We determined the hazard ratio, estimating the association between mortality and treatment. Non-inferiority was concluded in the primary comparison for either outcome if the upper limit of the two-sided 95% CI was ≤1.11, which is the margin used in the International Duration Evaluation of Adjuvant Chemotherapy Collaboration. Results: We included 3546 patients in the analysis of overall mortality; 486 (13.7%) received 50% and 3060 (86.3%) received >85% of a maximal course of therapy. Median follow-up was 5.4 years, and total follow-up was 20,510 person-years. There were 833 deaths. Treatment with 50% of a maximal course of adjuvant therapy was associated with a hazard ratio of 1.13 (95% CI 0.88 to 1.47) for overall mortality and a subdistribution hazard ratio of 1.31 (95% CI 0.91 to 1.87) for cancer-specific mortality versus >85% of a maximal course of therapy. In the secondary comparison, there was a trend toward higher overall mortality in patients treated with shorter durations of therapy, though confidence intervals overlapped considerably. Conclusion: We could not conclude that treatment with 50% of a maximal course is non-inferior to >85% of a maximal course of adjuvant therapy for mortality in stage III colon cancer. Clinicians and patients engaging in decision-making around treatment duration in this context should carefully consider the trade-off between treatment effectiveness and adverse effects of treatment.

Referenced by: doi:10.1016/j.annonc.2020.06.022 doi:10.9778/cmajo.20210046 doi:10.1016/s1470-2045(20)30527-1 doi:10.1001/jamanetworkopen.2019.4161 doi:10.1200/jco.19.00281 doi:10.1056/nejm199912303412706 doi:10.1093/annonc/mdu253 doi:10.1001/jamaoncol.2022.4445 doi:10.1371/journal.pmed.1001885 doi:10.1056/nejmoa1713709 doi:10.1200/jco.1986.4.1.115 doi:10.1200/jop.2014.001531 doi:10.1002/sim.7019 doi:10.1001/jamaoncol.2020.0809 doi:10.6004/jnccn.2020.7666 doi:10.1001/jamaoncol.2017.1016 doi:10.1097/mlr.0b013e318229360e doi:10.1093/gerona/62.7.731 doi:10.1007/s10654-018-0447-z doi:10.1080/01621459.2016.1260466 doi:10.1001/jama.2020.7819 doi:10.1161/circulationaha.115.017719 doi:10.1198/000313004x5824 doi:10.1056/nejme1906559 doi:10.1016/j.cjca.2020.11.010 doi:10.1002/sim.3618 doi:10.1002/9781119942283 doi:10.1177/0962280217713032 doi:10.1016/j.jclinepi.2021.06.004 doi:10.1001/jamanetworkopen.2019.4154 doi:10.1001/jamanetworkopen.2021.3587 doi:10.1002/ijc.33806 doi:10.1016/j.clcc.2021.09.008 doi:10.1002/cncr.24866 doi:10.1097/dcr.0000000000000966 doi:10.1503/cmaj.180962 doi:10.1200/jop.2017.023697 doi:10.1177/0969141320957361 doi:10.1016/j.clon.2016.09.001

{"container_title":"Current Oncology","content":{"parsed_at":1703189009,"parser":{"name":"textparser","version":"0.1.63"},"source":{"name":"pmc","version":"1.0.0"}},"first_page":6508,"issns":["1718-7729"],"issue":"7","last_page":6532,"publisher":"MDPI AG","volume":"30"}

2024-05-16